What you will find in the report cards
Pharmaceutical companies are all different in the ways they operate, where they have sales, which kinds of R&D they carry out and which products they have on the market. The Access to Medicine Index makes it possible to compare how these diverse companies perform when it comes to access to medicine.
Each Report Card includes a summary of the company's strengths and weaknesses, drivers behind changes in its ranking, as well as any best and innovative practices. The period of analysis for the 2018 Index is from 1 June 2016 to 31 May 2018.
The report cards are divided into six sections:
- Performance Explains the company’s 2018 ranking, including the drivers behind any movement, and the main areas where it scores well or poorly compared to peers.
- Changes since 2016 Pinpoints the most notable changes in the company's access-to-medicine performance since 2016, including new or expanded activities and programmes.
- Opportunities Sets out tailored opportunities for the company to expand access to medicine, taking account of its R&D pipeline, product portfolio, and other factors.
- Business Context Summarises the company’s operations, revenue per region and geographical reach, including any recent, relevant mergers and acquisitions.
- Portfolio and Pipeline Dives into the company’s portfolio of marketed products and pipeline of R&D products for the 77 diseases, conditions and pathogens in scope.
- Performance by Technical Area Details the company’s performance in each of the seven areas measured by the Index, including links to any best or innovative practices.
Explore and compare how the companies perform
On the new comparison hub, you can choose which companies to compare and which topic to put under the microscope. All of the figures and all of the analyses per Technical Area can be compared, for a maximum of three companies. Look for the icon in the top corner of the graphs. We have set the scale of each graph to show the highest level of detail per graph – so keep in mind that the scales will vary when comparing graphs side by side.
Where does the data come from?
The Index analyses 20 of the world’s largest research-based pharmaceutical companies. They are selected based on their size, market capitalisation and the relevance of their product portfolio and pipeline. Together, they account for 70% of global pharmaceutical revenues.
The report cards are a core part of the Access to Medicine Index analysis. The research team has analysed data from public sources and collected via a detailed survey of pharmaceutical companies regarding their policies and practices on access to medicine. Sources include the US FDA, the European Medicines Agency, ClinicalTrials.gov, annual filings and reports from companies, among others.
Data submitted by companies is verified, cross-checked and clarified by the research team using public sources and supporting documentation provided by the companies.
View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.